Association between prolactin receptor expression and proliferation in the endometrium of obese women with polycystic ovary syndrome

References

• Goodarzi MO, Dumesic DA, Chazenbalk G, et al. Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat Rev Endocrinol. 2011;7:219–231.
   PubMed Web of Science ®Google Scholar
• Rosenfield RL, Ehrmann DA. The pathogenesis of polycystic ovary syndrome (PCOS): the hypothesis of PCOS as functional ovarian hyperandrogenism revisited. Endocr Rev. 2016;37:467–520.
   PubMed Web of Science ®Google Scholar
• Piltonen TT. Polycystic ovary syndrome: endometrial markers. Best Pract Res Clin Obstet Gynaecol. 2016;37:66–79.
   PubMed Web of Science ®Google Scholar
• Goffin V, Binart N, Touraine P, et al. Prolactin: the new biology of an old hormone. Annu Rev Physiol. 2002;64:47–67.
   PubMed Web of Science ®Google Scholar
• Bernard V, Young J, Chanson P, et al. New insights in prolactin: pathological implications. Nat Rev Endocrinol. 2015;11:265–275.
   PubMed Web of Science ®Google Scholar
• Jones RL, Critchley HO, Brooks J, et al. Localization and temporal expression of prolactin receptor in human endometrium. J Clin Endocrinol Metab. 1998;83:258–262.
   PubMed Web of Science ®Google Scholar
• Ding K, Yuan Y, Chong QY, et al. Autocrine prolactin stimulates endometrial carcinoma growth and metastasis and reduces sensitivity to chemotherapy. Endocrinology. 2017;158:1595.
   PubMed Web of Science ®Google Scholar
• Levina VV, Nolen B, Su Y, et al. Biological significance of prolactin in gynecologic cancers. Cancer Res. 2009;69:5226–5233.
   PubMed Web of Science ®Google Scholar
• Al-Eisa E, Gabr SA, Alghadir AH. Effects of supervised aerobic training on the levels of anti-Mullerian hormone and adiposity measures in women with normo-ovulatory and polycystic ovary syndrome. J Pak Med Assoc. 2017;67:499–507.
   PubMed Web of Science ®Google Scholar
• Bahceci M, Tuzcu A, Bahceci S, et al. Is hyperprolactinemia associated with insulin resistance in non-obese patients with polycystic ovary syndrome? J Endocrinol Invest. 2003;26:655–659.
   PubMed Web of Science ®Google Scholar
• Franik G, Madej P, Guz-Lem M, et al. Daytime decrease of prolactin levels is associated with PCOS regardless to nutritional status and other hormones levels. Gynecol Endocrinol. 2017;33:336–341.
   PubMed Web of Science ®Google Scholar
• Murdoch AP, Dunlop W, Kendall-Taylor P, et al. The acute effects of a dopamine antagonist (domperidone) on luteinising hormone, follicule stimulating hormone, prolactin and thyrotrophin secretion in polycystic ovarian syndrome: differential effect of ovulation. Clin Endocrinol. 1984;21:611–619.
   PubMed Web of Science ®Google Scholar
• Szosland K, Pawlowicz P, Lewinski A. Prolactin secretion in polycystic ovary syndrome (PCOS). Neuroendocrinol Lett. 2015;36:53–58.
   PubMed Web of Science ®Google Scholar
• Moran LJ, Hutchison SK, Norman RJ, et al. Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2011;(2):CD007506.
   Google Scholar
• Nybacka A, Carlstrom K, Fabri F, et al. Serum antimullerian hormone in response to dietary management and/or physical exercise in overweight/obese women with polycystic ovary syndrome: secondary analysis of a randomized controlled trial. Fertil Steril. 2013;100:1096–1102.
   PubMed Web of Science ®Google Scholar
• Nybacka A, Carlstrom K, Stahle A, et al. Randomized comparison of the influence of dietary management and/or physical exercise on ovarian function and metabolic parameters in overweight women with polycystic ovary syndrome. Fertil Steril. 2011;96:1508–1513.
   PubMed Web of Science ®Google Scholar
• Ujvari U, Hulchiy M, Calaby A, et al. Lifestyle intervention up-regulates gene and protein levels of molecules involved in insulin signaling in the endometrium of overweight/obese women with polycystic ovary syndrome. Hum Reprod. 2014;29:1526–1535.
   PubMed Web of Science ®Google Scholar
• Hulchiy M, Nybacka A, Sahlin L, et al. Endometrial expression of estrogen receptors and the androgen receptor in women with polycystic ovary syndrome: a lifestyle intervention study. J Clin Endocrinol Metab. 2016;101:561–571.
   PubMed Web of Science ®Google Scholar
• Paulson M, Sahlin L, Hirschberg AL. Progesterone receptors and proliferation of the endometrium in obese women with polycystic ovary syndrome – a lifestyle intervention study. J Clin Endocrinol Metab. 2016;102:1244–1253.
   Web of Science ®Google Scholar
• Hulchiy M, Zhang H, Cline JM, et al. Effects of long-term tibolone treatment on nuclear sex steroid hormone receptors and G-protein-coupled estrogen receptor-1 expression in the macaque uterus. Menopause. 2012;19:332–338.
   PubMed Web of Science ®Google Scholar
• Barry JA, Azizia MM, Hardiman PJ. Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2014;20:748–758.
   PubMed Web of Science ®Google Scholar
• Wise MR, Jordan V, Lagas A, et al. Obesity and endometrial hyperplasia and cancer in premenopausal women: a systematic review. Am J Obstetr Gynecol. 2016;214:689e1–689e17.
   Web of Science ®Google Scholar
• Draca S. Prolactin as an immunoreactive agent. Immunol Cell Biol. 1995;73:481–483.
   PubMed Web of Science ®Google Scholar